ArticleInternational journal of molecular sciences2021
Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Diagnostic Potential of Circulating miRNAs in Glioma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision.Molecular therapy. Oncology · 2026Review
- Blood derived extracellular vesicles in patients with glioblastoma: preliminary experience from a monoinstitutional series.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The emerging role of miR-362 in cancer: expression and function across different cancer types.Medical oncology (Northwood, London, England) · 2025Review
- Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors.Molecular oncology · 2025Review
- Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.International journal of molecular sciences · 2025Review
- Over-expression of mir-181a-3p in serum of breast cancer patients as diagnostic biomarker.Molecular biology reports · 2024Article
- Circulating serum miR-362-3p and miR-6721-5p as potential biomarkers for classification patients with adult-type diffuse glioma.Frontiers in molecular biosciences · 2024Article
- Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration.Frontiers in oncology · 2024Review
- Assessment of NanoString technology as a tool for profiling circulating miRNA in maternal blood during pregnancy.Extracellular vesicles and circulating nucleic acids · 2024Article
- Analysis of Circulating Plasma MicroRNA Profile in Low-Grade and High-Grade Glioma - A Cross-Sectional Study.F1000Research · 2024Article
- Different miRNAs Related toInternational journal of molecular sciences · 2023Article
- Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs.BMC genomics · 2023Article
- Sonobiopsy for enrichment of circulating microRNAs in glioma patients.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs-besides being important regulators of cancer development-may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein-protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.